Keros Therapeutics CFO Keith Regnante resigns; Annita Tanini named interim CFO

Keros Therapeutics, Inc.

CFO Keith Regnante resigns effective Aug 3, 2026, voluntarily with no disagreement over accounting or controls.
Annita Tanini, Corporate Controller and VP Finance, appointed interim principal financial and accounting officer effective Aug 4, 2026.
Tanini receives $302,300 base salary, 30% target bonus, and severance of 6 months base plus COBRA.
Regnante receives only accrued salary and expenses; no additional severance.
Company has commenced search for a permanent CFO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.